{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T20:01:05Z","timestamp":1784145665653,"version":"3.55.0"},"reference-count":158,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["PI21\/01619"],"award-info":[{"award-number":["PI21\/01619"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["PI21\/01619"],"award-info":[{"award-number":["PI21\/01619"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["PI24\/01017"],"award-info":[{"award-number":["PI24\/01017"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.ctrv.2026.103124","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T16:37:49Z","timestamp":1774543069000},"page":"103124","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Biomarker-guided immunotherapy in gastric cancer: current insights and future perspectives"],"prefix":"10.1016","volume":"145","author":[{"given":"Mar","family":"Teixid\u00f3 Mulet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Veas Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Ter\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miquel","family":"Pi\u00f1ol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felip","family":"Vilardell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar","family":"Iglesias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinta","family":"Hierro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariona","family":"Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Matias-Guiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonieta","family":"Salud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep","family":"Tabernero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8455-4232","authenticated-orcid":false,"given":"Robert","family":"Montal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2026.103124_b0005","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0140-6736(20)31288-5","article-title":"Gastric cancer","volume":"396","author":"Smyth","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2026.103124_b0010","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","article-title":"Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Lordick","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103124_b0015","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nature13480","article-title":"Comprehensive molecular characterization of gastric adenocarcinoma","volume":"513","author":"Bass","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2026.103124_b0020","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41575-022-00703-w","article-title":"Current developments in gastric cancer: from molecular profiling to treatment strategy","volume":"20","author":"Alsina","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.ctrv.2026.103124_b0025","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.ctrv.2026.103124_b0030","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41571-021-00552-7","article-title":"Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways","volume":"19","author":"Kraehenbuehl","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103124_b0035","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","article-title":"The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy","volume":"19","author":"Havel","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ctrv.2026.103124_b0040","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1001\/jamaoncol.2020.3370","article-title":"Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial","volume":"6","author":"Shitara","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ctrv.2026.103124_b0045","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1200\/JCO.23.01601","article-title":"First-Line nivolumab plus chemotherapy for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 3-year follow-up of the phase III CheckMate 649 Trial","volume":"42","author":"Janjigian","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103124_b0050","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial","volume":"24","author":"Rha","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2026.103124_b0055","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study","volume":"398","author":"Sun","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2026.103124_b0060","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-078876","article-title":"Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial","volume":"385","author":"Qiu","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.ctrv.2026.103124_b0065","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1001\/jama.2023.19918","article-title":"Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: the ORIENT-16 randomized clinical trial","volume":"330","author":"Xu","year":"2023","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.ctrv.2026.103124_b0070","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S1470-2045(21)00692-6","article-title":"Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-contr","volume":"23","author":"Kang","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2026.103124_b0075","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1200\/JCO.20.00892","article-title":"Phase III trial of avelumab maintenance after first-line induction chemotherapy versus continuation of chemotherapy in patients with gastric cancers: results from JAVELIN Gastric 100","volume":"39","author":"Moehler","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103124_b0080","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1200\/JCO-25-00748","article-title":"Lenvatinib plus pembrolizumab and chemotherapy versus chemotherapy in advanced metastatic gastroesophageal adenocarcinoma: the phase III, Randomized LEAP-015 Study","volume":"43","author":"Shitara","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103124_b0085","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1038\/s41591-024-03450-4","article-title":"First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial","volume":"31","author":"Shen","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2026.103124_b0090","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/S0140-6736(23)02033-0","article-title":"Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial","volume":"402","author":"Janjigian","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2026.103124_b0095","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.canlet.2018.05.009","article-title":"Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFN\u03b3 secretion","volume":"430","author":"Chaganty","year":"2018","journal-title":"Cancer Lett"},{"key":"10.1016\/j.ctrv.2026.103124_b0100","doi-asserted-by":"crossref","unstructured":"Stein A, Paschold L, Tintelnot J, Goekkurt E, Henkes SS, Simnica D, et al. Efficacy of Ipilimumab vs FOLFOX in Combination with Nivolumab and Trastuzumab in Patients with Previously Untreated ERBB2-Positive Esophagogastric Adenocarcinoma: The AIO INTEGA Randomized Clinical Trial. JAMA Oncol., vol. 8, American Medical Association; 2022, p. 1150\u20138. DOI: 10.1001\/jamaoncol.2022.2228.","DOI":"10.1001\/jamaoncol.2022.2228"},{"key":"10.1016\/j.ctrv.2026.103124_b0105","doi-asserted-by":"crossref","unstructured":"Elimova E, Rha SY, Shitara K, Liu T. Zanidatamab + chemotherapy (CT) \u00b1 tislelizumab for first-line (1L) HER2-positive (HER2+) locally advanced, unresectable, or metastatic gastroesophageal adenocarcinoma (mGEA): Primary analysis from HERIZON-GEA-01. 2026 ASCO Gastrointest. Cancers Symp., vol. 44, 2026, p. LBA285. DOI: 10.1200\/JCO.2026.44.2_suppl.LBA285.","DOI":"10.1200\/JCO.2026.44.2_suppl.LBA285"},{"key":"10.1016\/j.ctrv.2026.103124_b0110","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(18)31257-1","article-title":"Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial","volume":"392","author":"Shitara","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2026.103124_b0115","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1093\/annonc\/mdy264","article-title":"Phase III, randomised trial of avelumab versus physician\u2019s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300","volume":"29","author":"Bang","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103124_b0120","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","article-title":"Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Kang","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2026.103124_b0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/ mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 Study","volume":"38","author":"Marabelle","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103124_b0130","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1001\/jamaoncol.2021.0275","article-title":"Assessment of pembrolizumab therapy for the treatment of microsatellite instability-high gastric or gastroesophageal junction cancer among patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials","volume":"7","author":"Chao","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ctrv.2026.103124_b0135","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S2468-1253(24)00156-0","article-title":"Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, pl","volume":"9","author":"Kang","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.ctrv.2026.103124_b0140","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.annonc.2024.10.829","article-title":"Adjuvant immunotherapy in patients with resected gastric and oesophagogastric junction cancer following preoperative chemotherapy with high risk for recurrence (ypN+ and\/or R1): European Organisation of Research and Treatment of Cancer (EORTC) 1707 VESTIG","volume":"36","author":"Lordick","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103124_b0145","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1056\/NEJMoa2032125","article-title":"Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer","volume":"384","author":"Kelly","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2026.103124_b0150","doi-asserted-by":"crossref","unstructured":"Kelly RJ, Ajani JA, Kuzdzal J, Zander T, Van Cutsem E, Piessen G, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC\/GEJC) following neoadjuvant chemoradiotherapy (CRT): First results of overall survival (OS) from CheckMate 577. 2025 ASCO Annu. Meet. I, 2025, p. 4000. DOI: 10.1200\/JCO.2025.43.16_suppl.4000.","DOI":"10.1200\/JCO.2025.43.16_suppl.4000"},{"key":"10.1016\/j.ctrv.2026.103124_b0155","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1200\/JCO.23.00975","article-title":"Perioperative atezolizumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable esophagogastric cancer: interim results from the randomized, multicenter, phase II\/III DANTE\/IKF-s633 Trial","volume":"42","author":"Lorenzen","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103124_b0160","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S1470-2045(23)00541-7","article-title":"Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study","volume":"25","author":"Shitara","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2026.103124_b0165","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2503701","article-title":"Perioperative durvalumab in gastric and gastroesophageal junction cancer","volume":"393","author":"Janjigian","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2026.103124_b0170","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1200\/JCO.24.00795","article-title":"Pathologic response of phase III study: perioperative camrelizumab plus rivoceranib and chemotherapy versus chemotherapy for locally advanced gastric cancer (DRAGON IV\/CAP 05)","volume":"43","author":"Li","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103124_b0175","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1200\/JCO.22.00686","article-title":"Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair\/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma: the GERCOR NEONIPIGA phase II Study","volume":"41","author":"Andr\u00e9","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103124_b0180","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.annonc.2024.11.016","article-title":"Tremelimumab and durvalumab as neoadjuvant or non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: the INFINITY study by GONO","volume":"36","author":"Raimondi","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103124_b0185","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41571-021-00492-2","article-title":"Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies","volume":"18","author":"Nakamura","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103124_b0190","doi-asserted-by":"crossref","first-page":"22699","DOI":"10.1073\/pnas.1821218116","article-title":"Combination anti\u2013CTLA-4 plus anti\u2013PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies","volume":"116","author":"Wei","year":"2019","journal-title":"PNAS"},{"key":"10.1016\/j.ctrv.2026.103124_b0195","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1200\/JCO-24-02463","article-title":"Phase II study (NO LIMIT, WJOG13320G) of first-line nivolumab plus low-dose ipilimumab for microsatellite instability-high advanced gastric or esophagogastric junction cancer","volume":"43","author":"Kawakami","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103124_b0200","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1158\/2159-8290.CD-20-1445","article-title":"Design and efficacy of a monovalent bispecific PD-1\/CTLA4 antibody that enhances CTLA4 blockade on PD-1+ activated T cells","volume":"11","author":"Dovedi","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ctrv.2026.103124_b0205","article-title":"Neoadjuvant cadonilimab plus FLOT chemotherapy in locally advanced gastric\/gastroesophageal junction adenocarcinoma: a multicenter, phase 2 study","volume":"6","author":"Long","year":"2025","journal-title":"Med (New York, NY)"},{"key":"10.1016\/j.ctrv.2026.103124_b0210","article-title":"Novel immunotherapeutic approaches in gastric cancer. Precis","volume":"7","author":"Yang","year":"2024","journal-title":"Clin Med"},{"key":"10.1016\/j.ctrv.2026.103124_b0215","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1200\/JCO.23.01636","article-title":"First-line nivolumab and relatlimab plus chemotherapy for gastric or gastroesophageal junction adenocarcinoma: the phase II RELATIVITY-060 Study","volume":"42","author":"Hegewisch-Becker","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103124_b0220","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/s41591-024-02877-z","article-title":"Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal\/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses","volume":"30","author":"Kelly","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2026.103124_b0225","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1038\/s41591-025-04022-w","article-title":"Domvanalimab and zimberelimab in advanced gastric, gastroesophageal junction or esophageal cancer: a phase 2 trial","volume":"31","author":"Janjigian","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2026.103124_b0230","doi-asserted-by":"crossref","first-page":"4197","DOI":"10.1038\/s41591-025-03979-y","article-title":"Perioperative pembrolizumab, trastuzumab and FLOT in HER2-positive localized esophagogastric adenocarcinoma: a phase 2 trial","volume":"31","author":"Stein","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2026.103124_b0235","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1001\/jamaoncol.2025.0522","article-title":"Atezolizumab and trastuzumab plus chemotherapy for ERBB2-positive locally advanced resectable gastric cancer: a randomized clinical trial","volume":"11","author":"Peng","year":"2025","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ctrv.2026.103124_b0240","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41420-025-02429-5","article-title":"Navigating the future of gastric cancer treatment: a review on the impact of antibody-drug conjugates","volume":"11","author":"Yin","year":"2025","journal-title":"Cell Death Discov"},{"key":"10.1016\/j.ctrv.2026.103124_b0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102415","article-title":"Disitamab vedotin (RC48) plus toripalimab for HER2-expressing advanced gastric or gastroesophageal junction and other solid tumours: a multicentre, open label, dose escalation and expansion phase 1 trial","volume":"68","author":"Wang","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.ctrv.2026.103124_b0250","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41392-024-01773-9","article-title":"First-line camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and chemotherapy for advanced gastric cancer (SPACE): a phase 1 study","volume":"9","author":"Chen","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.ctrv.2026.103124_b0255","doi-asserted-by":"crossref","unstructured":"Wang C, Huang M, Dai Y, Feng W, Zhao X, Zhu X. Fruquintinib combined with PD-1 inhibitors and chemotherapy in the first-line treatment of HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma (FDZL-FIX): A single-arm, open-label phase 2 study. 2025 ASCO Gastrointest. Cancers Symp., vol. 43, 2025, p. 461. DOI: 10.1200\/jco.2025.43.4_suppl.461.","DOI":"10.1200\/JCO.2025.43.4_suppl.461"},{"key":"10.1016\/j.ctrv.2026.103124_b0260","doi-asserted-by":"crossref","unstructured":"Goldstein D, Sjoquist K, Espinosa D, Rha SY, Goetze TO, Tebbutt N, et al. Regorafenib plus nivolumab vs investigator\u2019s choice of chemotherapy in previously treated gastric or gastroesophageal cancer: INTEGRATE IIb, a randomized phase 3 AGITG Intergroup [NHMRC-CTC\/IKF\/AIO, ACCRU, TCOG\/NHRI] study. ESMO Congr. 2025, vol. 36, Elsevier; 2025, p. S1737\u20138. DOI: 10.1016\/j.annonc.2025.09.095.","DOI":"10.1016\/j.annonc.2025.09.095"},{"key":"10.1016\/j.ctrv.2026.103124_b0265","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41467-022-35431-x","article-title":"Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer","volume":"14","author":"Li","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.ctrv.2026.103124_b0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2023.121459","article-title":"Current progress and challenges of immunotherapy in gastric cancer: a focus on CAR-T cells therapeutic approach","volume":"318","author":"Entezam","year":"2023","journal-title":"Life Sci"},{"key":"10.1016\/j.ctrv.2026.103124_b0275","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1186\/s12876-023-02924-y","article-title":"CLDN18.2 expression and its impact on prognosis and the immune microenvironment in gastric cancer","volume":"23","author":"Wang","year":"2023","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.ctrv.2026.103124_b0280","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/s41591-022-01800-8","article-title":"Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results","volume":"28","author":"Qi","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2026.103124_b0285","doi-asserted-by":"crossref","unstructured":"Zhou Y, Li Q, Li W, Lu L, Xiao S, Cai Y, et al. Clinical results of a phase 1 trial evaluating a HER2 directed CAR-T product selective for the tumor microenvironment (TME) in patients with GI and other solid tumor malignancies. 2025 ASCO Gastrointest. Cancers Symp., vol. 43, 2025, p. 449. DOI: 10.1200\/jco.2025.43.4_suppl.449.","DOI":"10.1200\/JCO.2025.43.4_suppl.449"},{"key":"10.1016\/j.ctrv.2026.103124_b0290","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","article-title":"Approaches to treat immune hot, altered and cold tumours with combination immunotherapies","volume":"18","author":"Galon","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ctrv.2026.103124_b0295","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/2162402X.2018.1544442","article-title":"PD-L1 and immune infiltrates are differentially expressed in distinct subgroups of gastric cancer","volume":"8","author":"Angell","year":"2019","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ctrv.2026.103124_b0300","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1158\/1078-0432.CCR-22-0121","article-title":"Association of tumor mutational burden with efficacy of pembrolizumab\u00b1chemotherapy as first-line therapy for gastric cancer in the phase III KEYNOTE-062 study","volume":"28","author":"Lee","year":"2022","journal-title":"Clin Cancer Res an Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103124_b0305","doi-asserted-by":"crossref","first-page":"3905","DOI":"10.1038\/s41467-025-58958-1","article-title":"T-bet+CD8+ T cells govern anti-PD-1 responses in microsatellite-stable gastric cancers","volume":"16","author":"Tang","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.ctrv.2026.103124_b0310","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nature14404","article-title":"Melanoma-intrinsic \u03b2-catenin signalling prevents anti-tumour immunity","volume":"523","author":"Spranger","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2026.103124_b0315","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1158\/1078-0432.CCR-18-1942","article-title":"WNT\/b-catenin pathway activation correlates with immune exclusion across human cancers","volume":"25","author":"Luke","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103124_b0320","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ccell.2017.04.003","article-title":"Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy","volume":"31","author":"Spranger","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ctrv.2026.103124_b0325","first-page":"4401","article-title":"EHD3 promotes gastric cancer progression via Wnt\/\u03b2-catenin\/EMT pathway and associates with clinical prognosis and immune infiltration","volume":"13","author":"Yu","year":"2023","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103124_b0330","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.canlet.2021.06.008","article-title":"Beta2-microglobulin(B2M) in cancer immunotherapies: biological function, resistance and remedy","volume":"517","author":"Wang","year":"2021","journal-title":"Cancer Lett"},{"key":"10.1016\/j.ctrv.2026.103124_b0335","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1158\/2159-8290.CD-17-0593","article-title":"Impaired HLA class I antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung cancer","volume":"7","author":"Gettinger","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ctrv.2026.103124_b0340","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1200\/JCO.23.00580","article-title":"Genomic and immunophenotypic landscape of acquired resistance to PD-(L)1 blockade in non-small-cell lung cancer","volume":"42","author":"Ricciuti","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103124_b0345","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.trecan.2024.03.008","article-title":"Gastric cancer immunosuppressive microenvironment heterogeneity: implications for therapy development","volume":"10","author":"Yasuda","year":"2024","journal-title":"Trends Cancer"},{"key":"10.1016\/j.ctrv.2026.103124_b0350","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-025-07385-7","article-title":"Overcoming immunotherapy resistance in gastric cancer: insights into mechanisms and emerging strategies","volume":"16","author":"Luo","year":"2025","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.ctrv.2026.103124_b0355","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2023.1285343","article-title":"Resistance to immune checkpoint inhibitors in gastric cancer","volume":"14","author":"Liu","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ctrv.2026.103124_b0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215598","article-title":"PMN-MDSCs accumulation induced by CXCL1 promotes CD8+ T cells exhaustion in gastric cancer","volume":"532","author":"Zhou","year":"2022","journal-title":"Cancer Lett"},{"key":"10.1016\/j.ctrv.2026.103124_b0365","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1136\/gutjnl-2018-316324","article-title":"Tumour-associated macrophages-derived CXCL8 determines immune evasion through autonomous PD-L1 expression in gastric cancer","volume":"68","author":"Lin","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.ctrv.2026.103124_b0370","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1408700","article-title":"Prognostic value of inflammatory markers NLR, PLR, and LMR in gastric cancer patients treated with immune checkpoint inhibitors: a meta-analysis and systematic review","volume":"15","author":"Tan","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.ctrv.2026.103124_b0375","doi-asserted-by":"crossref","unstructured":"Budczies J, Bockmayr M, Klauschen F, Endris V, Schirmacher P, Denkert C, et al. Mutation patterns in genes encoding interferon signaling and antigen presentation\u00a0: A pan-cancer survey with implications for the use of immune checkpoint inhibitors 2017:651\u20139. DOI: 10.1002\/gcc.22468.","DOI":"10.1002\/gcc.22468"},{"key":"10.1016\/j.ctrv.2026.103124_b0380","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.cell.2016.03.031","article-title":"Combination cancer therapies with immune checkpoint blockade\u00a0: convergence on interferon signaling","volume":"165","author":"Minn","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.ctrv.2026.103124_b0385","doi-asserted-by":"crossref","unstructured":"Adler AJ, Ryan JM, Zhou B, Jeffrey S. Cytokines and metabolic factors regulate tumoricidal T-cell function during cancer immunotherapy 2017;9:71\u201382. DOI: 10.2217\/imt-2016-0097.","DOI":"10.2217\/imt-2016-0097"},{"key":"10.1016\/j.ctrv.2026.103124_b0390","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.molmed.2017.11.005","article-title":"Metabolic Control of CD8 + T cell fate decisions and antitumor immunity","volume":"24","author":"Zhang","year":"2018","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.ctrv.2026.103124_b0395","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/s42255-020-00280-9","article-title":"Metabolic and epigenetic regulation of T-cell exhaustion","volume":"2","author":"Franco","year":"2020","journal-title":"Nat Metab"},{"key":"10.1016\/j.ctrv.2026.103124_b0400","first-page":"727","article-title":"PD-1\/PD-L1 pathway: current researches in cancer","volume":"10","author":"Han","year":"2020","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103124_b0405","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2024.155743","article-title":"Immune biomarkers and predictive signatures in gastric cancer: optimizing immunotherapy responses","volume":"265","author":"Vickram","year":"2025","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.ctrv.2026.103124_b0410","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1136\/gutjnl-2015-310839","article-title":"Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma","volume":"66","author":"Thompson","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.ctrv.2026.103124_b0415","article-title":"PD-L1 immunohistochemistry in gastric cancer: comparison of combined positive score and tumor area positivity across 28-8, 22C3, and SP263 assays","volume":"8","author":"Klempner","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ctrv.2026.103124_b0420","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-000791","article-title":"Current status and future potential of predictive biomarkers for immune checkpoint inhibitors in gastric cancer","volume":"5","author":"Kang","year":"2020","journal-title":"ESMO Open"},{"key":"10.1016\/j.ctrv.2026.103124_b0425","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1093\/annonc\/mdz116","article-title":"ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1\/PD-L1 expression and tumour mutational burden: a systematic review-based approach","volume":"30","author":"Luchini","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103124_b0430","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1111\/cas.16160","article-title":"Microsatellite instability: a 2024 update","volume":"115","author":"Yamamoto","year":"2024","journal-title":"Cancer Sci"},{"key":"10.1016\/j.ctrv.2026.103124_b0435","doi-asserted-by":"crossref","first-page":"112103","DOI":"10.18632\/oncotarget.22783","article-title":"Hypermutation and microsatellite instability in gastrointestinal cancers","volume":"8","author":"Yuza","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctrv.2026.103124_b0440","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.pharmthera.2018.04.004","article-title":"DNA mismatch repair in cancer","volume":"189","author":"Baretti","year":"2018","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.ctrv.2026.103124_b0445","first-page":"5248","article-title":"A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer","volume":"58","author":"Boland","year":"1998","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103124_b0450","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/cas.13837","article-title":"Next generation sequencing-based gene panel tests for the management of solid tumors","volume":"110","author":"Nagahashi","year":"2019","journal-title":"Cancer Sci"},{"key":"10.1016\/j.ctrv.2026.103124_b0455","doi-asserted-by":"crossref","first-page":"763","DOI":"10.3389\/fonc.2020.00763","article-title":"Predictive biomarkers of immune checkpoint inhibition in gastroesophageal cancers","volume":"10","author":"Sundar","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctrv.2026.103124_b0460","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41571-024-00932-9","article-title":"Tumour mutational burden: clinical utility, challenges and emerging improvements","volume":"21","author":"Budczies","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103124_b0465","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1158\/2159-8290.CD-14-0863","article-title":"The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints","volume":"5","author":"Llosa","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ctrv.2026.103124_b0470","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2026.103124_b0475","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2020.100036","article-title":"Predictive role of microsatellite instability for PD-1 blockade in patients with advanced gastric cancer\u00a0: a meta-analysis of randomized clinical trials","volume":"6","author":"Pietrantonio","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.ctrv.2026.103124_b0480","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/jamaoncol.2016.6762","article-title":"Mismatch repair deficiency, microsatellite instability, and survival: an exploratory analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) trial","volume":"3","author":"Smyth","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ctrv.2026.103124_b0485","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/SLA.0000000000002803","article-title":"Microsatellite instability and programmed cell death-ligand 1 expression in Stage II\/III gastric cancer: post hoc analysis of the CLASSIC randomized controlled study","volume":"270","author":"Choi","year":"2019","journal-title":"Ann Surg"},{"key":"10.1016\/j.ctrv.2026.103124_b0490","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1750-9378-7-21","article-title":"Epstein-barr virus infected gastric adenocarcinoma expresses latent and lytic viral transcripts and has a distinct human gene expression profile","volume":"7","author":"Tang","year":"2012","journal-title":"Infect Agent Cancer"},{"key":"10.1016\/j.ctrv.2026.103124_b0495","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ctrv.2018.03.006","article-title":"Outlooks on Epstein-Barr virus associated gastric cancer","volume":"66","author":"Naseem","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ctrv.2026.103124_b0500","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1038\/s41591-018-0101-z","article-title":"Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer","volume":"24","author":"Kim","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2026.103124_b0505","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s10120-018-0880-4","article-title":"EBV-associated gastric cancer evades T-cell immunity by PD-1\/PD-L1 interactions","volume":"22","author":"Sasaki","year":"2019","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.ctrv.2026.103124_b0510","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1038\/s41591-025-03575-0","article-title":"Nivolumab plus chemotherapy or ipilimumab in gastroesophageal cancer: exploratory biomarker analyses of a randomized phase 3 trial","volume":"31","author":"Shitara","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2026.103124_b0515","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004080","article-title":"Efficacy and predictive biomarkers of immunotherapy in Epstein-Barr virus-associated gastric cancer","volume":"10","author":"Bai","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ctrv.2026.103124_b0520","first-page":"5006","article-title":"PD-1 antibody camrelizumab for Epstein-Barr virus-positive metastatic gastric cancer: a single-arm, open-label, phase 2 trial","volume":"11","author":"Sun","year":"2021","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103124_b0525","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ccell.2020.10.001","article-title":"The challenges of tumor mutational burden as an immunotherapy biomarker","volume":"39","author":"Jardim","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ctrv.2026.103124_b0530","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med"},{"key":"10.1016\/j.ctrv.2026.103124_b0535","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types","volume":"51","author":"Samstein","year":"2019","journal-title":"Nat Genet"},{"key":"10.1016\/j.ctrv.2026.103124_b0540","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2026.103124_b0545","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1158\/2159-8290.CD-20-1408","article-title":"Personalized antibodies for gastroesophageal adenocarcinoma (Pangea): a phase ii study evaluating an individualized treatment strategy for metastatic disease","volume":"11","author":"Catenacci","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ctrv.2026.103124_b0550","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1093\/annonc\/mdz197","article-title":"Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib\/II clinical trial NCT02915432","volume":"30","author":"Wang","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103124_b0555","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1186\/s12885-022-09488-2","article-title":"Predictive biomarkers for the efficacy of nivolumab as \u2265 3rd-line therapy in patients with advanced gastric cancer: a subset analysis of ATTRACTION-2 phase III trial","volume":"22","author":"Kim","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2026.103124_b0560","doi-asserted-by":"crossref","first-page":"15321","DOI":"10.3390\/ijms242015321","article-title":"Predictive biomarkers for immunotherapy in gastric cancer: current status and emerging prospects","volume":"24","author":"Hou","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ctrv.2026.103124_b0565","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ctrv.2026.103124_b0570","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S1470-2045(16)00175-3","article-title":"Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial","volume":"17","author":"Muro","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2026.103124_b0575","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-006920","article-title":"Association between gene expression signatures and clinical outcomes of pembrolizumab versus paclitaxel in advanced gastric cancer: Exploratory analysis from the randomized, controlled, phase III KEYNOTE-061 trial","volume":"11","author":"Shitara","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ctrv.2026.103124_b0580","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2018.0013","article-title":"Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial","volume":"4","author":"Fuchs","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ctrv.2026.103124_b0585","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1158\/2326-6066.CIR-18-0436","article-title":"Tumor microenvironment characterization in gastric cancer identifies prognostic and immunotherapeutically relevant gene signatures","volume":"7","author":"Zeng","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.ctrv.2026.103124_b0590","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010024","article-title":"Comprehensive immunophenotyping of gastric adenocarcinoma identifies an inflamed class of tumors amenable to immunotherapies","volume":"13","author":"Veas Rodriguez","year":"2025","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ctrv.2026.103124_b0595","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.it.2020.06.002","article-title":"The contribution of epigenetics to cancer immunotherapy","volume":"41","author":"Villanueva","year":"2020","journal-title":"Trends Immunol"},{"key":"10.1016\/j.ctrv.2026.103124_b0600","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.3390\/ijms25063381","article-title":"Gastric cancer in the era of epigenetics","volume":"25","author":"Christodoulidis","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ctrv.2026.103124_b0605","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106245","article-title":"Epigenetically silenced PD-L1 confers drug resistance to anti-PD1 therapy in gastric cardia adenocarcinoma","volume":"82","author":"Zhu","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.ctrv.2026.103124_b0610","doi-asserted-by":"crossref","first-page":"639","DOI":"10.2217\/epi-2018-0149","article-title":"Clinicopathological, immune and molecular correlates of PD-L2 methylation in gastric adenocarcinomas","volume":"11","author":"Lingohr","year":"2019","journal-title":"Epigenomics"},{"key":"10.1016\/j.ctrv.2026.103124_b0615","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1158\/2159-8290.CD-16-1022","article-title":"Epigenomic promoter alterations amplify gene isoform and immunogenic diversity in gastric adenocarcinoma","volume":"7","author":"Qamra","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ctrv.2026.103124_b0620","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1093\/annonc\/mdy550","article-title":"Epigenomic promoter alterations predict for benefit from immune checkpoint inhibition in metastatic gastric cancer","volume":"30","author":"Sundar","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103124_b0625","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ccell.2024.11.009","article-title":"Advances in liquid biopsy: from exploration to practical application","volume":"43","author":"Alix-Panabi\u00e8res","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ctrv.2026.103124_b0630","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s12943-020-01274-7","article-title":"The predicting role of circulating tumor DNA landscape in gastric cancer patients treated with immune checkpoint inhibitors","volume":"19","author":"Jin","year":"2020","journal-title":"Mol Cancer"},{"key":"10.1016\/j.ctrv.2026.103124_b0635","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/s43856-025-00867-x","article-title":"Circulating tumor DNA strongly predicts efficacy of chemotherapy plus immune checkpoint inhibitors in patients with advanced gastro-esophageal adenocarcinoma","volume":"5","author":"Tougeron","year":"2025","journal-title":"Commun Med"},{"key":"10.1016\/j.ctrv.2026.103124_b0640","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1438111","article-title":"Dynamic change of PD-L1 expression on circulating tumor cells in advanced solid tumor patients undergoing PD-1 blockade therapy","volume":"7","author":"Yue","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ctrv.2026.103124_b0645","doi-asserted-by":"crossref","first-page":"7887","DOI":"10.2147\/OTT.S223222","article-title":"Enumeration and characterization of circulating tumor cells and its application in advanced gastric cancer","volume":"12","author":"Cheng","year":"2019","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.ctrv.2026.103124_b0650","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-006678","article-title":"First-line treatment of unresectable or metastatic HER2 positive esophagogastric adenocarcinoma: liquid biomarker analysis of the phase 2 INTEGA trial","volume":"11","author":"Paschold","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ctrv.2026.103124_b0655","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.annonc.2021.09.010","article-title":"Harmful cytokines in cancer immunology and immunotherapy: biomarkers and targets?","volume":"32","author":"Melero","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103124_b0660","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s10238-025-01676-1","article-title":"Cytokine profiles as predictive biomarkers for treatment outcomes in advanced gastric cancer patients undergoing PD-1 blockade immunochemotherapy: a meta-analysis","volume":"25","author":"Yang","year":"2025","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.ctrv.2026.103124_b0665","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s10120-023-01435-9","article-title":"Second-line chemoimmunotherapy with nivolumab and paclitaxel in immune-related biomarker-enriched advanced gastric cancer: a multicenter phase Ib\/II study","volume":"27","author":"Lee","year":"2024","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.ctrv.2026.103124_b0670","doi-asserted-by":"crossref","DOI":"10.1002\/jev2.12209","article-title":"Plasma extracellular vesicle derived protein profile predicting and monitoring immunotherapeutic outcomes of gastric cancer","volume":"11","author":"Zhang","year":"2022","journal-title":"J Extracell Vesicles"},{"key":"10.1016\/j.ctrv.2026.103124_b0675","doi-asserted-by":"crossref","first-page":"6336","DOI":"10.21037\/tcr-24-2151","article-title":"The efficacy of plasma exosomal miRNAs as predictive biomarkers for PD-1 blockade plus chemotherapy in gastric cancer","volume":"13","author":"Hua","year":"2024","journal-title":"Transl Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103124_b0680","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/s41571-023-00803-9","article-title":"Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors","volume":"20","author":"Simpson","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103124_b0685","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1136\/gutjnl-2017-314205","article-title":"Gastric microbial community profiling reveals a dysbiotic cancer-associated microbiota","volume":"67","author":"Ferreira","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.ctrv.2026.103124_b0690","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1136\/gutjnl-2020-323392","article-title":"Helicobacter pylori infection has a detrimental impact on the efficacy of cancer immunotherapies","volume":"71","author":"Oster","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.ctrv.2026.103124_b0695","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1186\/s12885-022-10004-9","article-title":"Association of Helicobacter pylori infection with survival outcomes in advanced gastric cancer patients treated with immune checkpoint inhibitors","volume":"22","author":"Che","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2026.103124_b0700","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2023.101251","article-title":"Prior antibiotic administration disrupts anti-PD-1 responses in advanced gastric cancer by altering the gut microbiome and systemic immune response","volume":"4","author":"Kim","year":"2023","journal-title":"Cell Reports Med"},{"key":"10.1016\/j.ctrv.2026.103124_b0705","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1158\/2767-9764.CRC-24-0543","article-title":"Microbiome landscape and association with response to immune checkpoint inhibitors in advanced solid tumors: a SCRUM-Japan MONSTAR-SCREEN study","volume":"5","author":"Sawada","year":"2025","journal-title":"Cancer Res Commun"},{"key":"10.1016\/j.ctrv.2026.103124_b0710","doi-asserted-by":"crossref","first-page":"e1312","DOI":"10.1002\/ctm2.1312","article-title":"The gut microbiome affects response of treatments in HER2\u2010negative advanced gastric cancer","volume":"13","author":"Han","year":"2023","journal-title":"Clin Transl Med"},{"key":"10.1016\/j.ctrv.2026.103124_b0715","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.annonc.2023.10.125","article-title":"Artificial intelligence for predictive biomarker discovery in immuno-oncology: a systematic review","volume":"35","author":"Prelaj","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103124_b0720","first-page":"33","article-title":"Advancing precision medicine: the transformative role of artificial intelligence in immunogenomics, radiomics, and pathomics for biomarker discovery and immunotherapy optimization","volume":"22","author":"Chang","year":"2025","journal-title":"Cancer Biol Med"},{"key":"10.1016\/j.ctrv.2026.103124_b0725","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtbi.2024.111816","article-title":"A muti-modal feature fusion method based on deep learning for predicting immunotherapy response","volume":"586","author":"Li","year":"2024","journal-title":"J Theor Biol"},{"key":"10.1016\/j.ctrv.2026.103124_b0730","article-title":"Machine learning-based cell death signature for predicting the prognosis and immunotherapy benefit in stomach adenocarcinoma","volume":"103","author":"Li","year":"2024","journal-title":"Med"},{"key":"10.1016\/j.ctrv.2026.103124_b0735","doi-asserted-by":"crossref","first-page":"23328","DOI":"10.1038\/s41598-024-74907-2","article-title":"Machine learning based intratumor heterogeneity signature for predicting prognosis and immunotherapy benefit in stomach adenocarcinoma","volume":"14","author":"Chen","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.ctrv.2026.103124_b0740","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/s41571-019-0252-y","article-title":"Artificial intelligence in digital pathology \u2014 new tools for diagnosis and precision oncology","volume":"16","author":"Bera","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103124_b0745","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/j.ajpath.2023.06.004","article-title":"Deep learning\u2013based stratification of gastric cancer patients from hematoxylin and eosin\u2013stained whole slide images by predicting molecular features for immunotherapy response","volume":"193","author":"Wei","year":"2023","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ctrv.2026.103124_b0750","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/s41591-019-0462-y","article-title":"Deep learning can predict microsatellite instability directly from histology in gastrointestinal cancer","volume":"25","author":"Kather","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2026.103124_b0755","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1038\/s41467-024-45589-1","article-title":"Regression-based Deep-Learning predicts molecular biomarkers from pathology slides","volume":"15","author":"El Nahhas","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.ctrv.2026.103124_b0760","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1186\/s12967-024-05262-z","article-title":"Deep learning based digital pathology for predicting treatment response to first-line PD-1 blockade in advanced gastric cancer","volume":"22","author":"Liu","year":"2024","journal-title":"J Transl Med"},{"key":"10.1016\/j.ctrv.2026.103124_b0765","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-008927","article-title":"Development and interpretation of a pathomics-driven ensemble model for predicting the response to immunotherapy in gastric cancer","volume":"12","author":"Han","year":"2024","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ctrv.2026.103124_b0770","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/s41586-024-08378-w","article-title":"A vision\u2013language foundation model for precision oncology","volume":"638","author":"Xiang","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2026.103124_b0775","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1200\/JCO.22.00686","article-title":"Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair\/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma: the GERCOR NEONIPIGA phase II Study","volume":"41","author":"Andr\u00e9","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103124_b0780","first-page":"1","article-title":"Validation of biomarkers to predict response to immunotherapy in cancer\u00a0: volume II \u2014 clinical validation and regulatory considerations","author":"Dobbin","year":"2016","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ctrv.2026.103124_b0785","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jtho.2021.01.1616","article-title":"Biomarker discovery and validation: statistical considerations","volume":"16","author":"Ou","year":"2022","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2026.103124_b0790","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41571-021-00473-5","article-title":"PD-L1 as a biomarker of response to immune-checkpoint inhibitors","volume":"18","author":"Doroshow","year":"2021","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226000381?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226000381?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T23:20:55Z","timestamp":1779232855000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737226000381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":158,"alternative-id":["S0305737226000381"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103124","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biomarker-guided immunotherapy in gastric cancer: current insights and future perspectives","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103124","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103124"}}